已培養了8名碩士;正在培養碩士生6人。先后在國內外學(xué)術(shù)雜志上發(fā)表60余篇文章,參編出版《生物醫藥前沿技術(shù)》。參與成功研制開(kāi)發(fā)一類(lèi)新藥2個(gè),III類(lèi)醫療器械一項。 近五年代表性論著(zhù)
1. 生物醫藥前沿技術(shù),副主編,人民衛生出版社,2004。
近五年代表性論文
1.Qing Zheng, Zhifeng Huang, Xiaoping Wu?, Zhijian Su, Hua Xu, Wen Zhao, Yadong Huang, Xiaokun Li. Site-directed chemical modification of recombinant human aFGF Mutant with polyethylene glycol, Chinese Chemical letters, 2005,16(8):1013-1016 .
2.Xiaoping Wu, Xiaokun Li, Zhijian Su, Qing Zheng*, Hua Xu, Sixian Wu, Ya Feng and Wen Zhao. Expression and Purification of Soluble Non-Fusion Vasostatin in Escherichia coli. Protein & Peptide Letters, 2005, 12(7): 659-662. 3.Zhifeng Huang, Qing Zheng, Xiaoping Wu, Zhijian Su, Hua Xu,Yi Tan, Wenke Feng, Xiaokun Li?, Lu Cai. Enhanced protection of modified human acidic fibroblast growth factor with polyethylene glycol against ischemia/ reperfusion- induced retinal damage in rats, Toxicology Letters, 2007, 170(2): 146 -156. 4.Xiaoping Wu, Xiaokun Li, Yaoying Zeng, Qing Zheng, Sixian Wu. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expression and Purification,2006,48(1): 24-27.
5.Xiaoping Wu, Zhijian Su, Xiaokun Li, Qing Zheng, Yadong Huang, Hui Yuan. High-level expression and purification of a nonmitogenic form of human acidic fibroblast growth factor in Escherichia coli. Protein Expression and Purification,2005, 42(1):7-11.
6.Zhijian Su, Yadong Huang, Quannan Zhou, Zhiling Wu, Xiaoping Wu, Qing Zheng, Changcai Ding and Xiaokun Li. High-level expression and purification of human epidermal growth factor with SUMO fusion in Escherichia coli. Protein Peptide Letters. 2006,13(8):785-792. 7.Xu H, Yang JN, Li XK, Zheng Q, Zhao W, Su ZJ, Huang YD. Retina Protective Effect of Acidic Fibroblast Growth Factor after Canceling Its Mitogenic Activity. Journal of ocular pharmacology and therapeutics. 2008, 24(5): 445-451.
8.Xu H, Hai GF, Xiang JZ, Yao CC, Zheng Q, Zhang QH, Hong H. Protective effect of non-mitogenic human acidic fibroblast growth factor on hepatocyte injury. Hepatology Research 2007; 37: 836–844.
9.WU Xiao-Ping, SU Zhi-jian, ZHENG Qing, WU Si-xian, XU Hua, Zhao Wen, LI Xiao-Kun. A Convenient and Effective Approach for Gene Synthesis of Human Platelet Factor2. Journal of China Pharmaceutical University, 2005,36(6):590-59. 10.WU Xiao-Ping, SU Zhi-jian, ZHENG Qing, WU Si-xian, FENG Ya, QU Hong-yan, XU Hua, LI Xiao-Kun Expression and Purification of a hbFGF Lacking Nuclear Localization Signal, Journal of China Pharmaceutical University 2005,36(3):272-27.
11. WU Xiao-ping LI Xiao-kun SU Zhi-jian ZHENG Qing WU Si-xian XU Hua QU Hong-yan. Expression and Purification of Basic Fibroblast Growth Factor Mutant with Reduced Mitogenic Activity,China Biotechnology, 2005, 25 (2) :49-52.
12.鄭青, 郭建紅, 周仲樓, 曾慶平, 趙文. 轉鐵蛋白對青蒿琥酯體外抗腫瘤活性的增效作用研究,中草藥,2008,39(6):887-889. 13.鄭青, 彭菲, 吳曉萍, 蘇志堅, 李校堃. nmhaFGF對人乳腺癌細胞增殖的影響及相關(guān)機制. 藥學(xué)學(xué)報. 2006, 41(3): 263-267. 14.鄭青, 彭菲, 蘇志堅, 吳曉萍, 許華, 李校堃. haFGF和nm-haFGF過(guò)表達對乳腺腫瘤細胞增殖及c-fos、c-jun mRNA表達的影響. 中國藥理學(xué)通報. 2006, 22(4): 402-7.
15.鄭 青, 高樹(shù)生, 彭菲, 李黎, 許華, 劉蓓, 李校堃. bFGF-膠原蛋白海綿對宮頸糜爛的治療作用,山東醫藥,2006,46(11):41-42. 16.人酸性成纖維細胞生長(cháng)因子突變體表達與修飾, 華南理工大學(xué)學(xué)報,2005,33(1):88-91.
17.鄭青, 汪小鳳, 吳曉萍, 許華, 張齊好, 蘇志堅, 李校堃. haFGF突變體促細胞增殖活性降低及其機制,中國病理生理雜志,2005, 21(3):446-448. 18.汪小鳳, 鄭青*, 蔡紹暉, 吳曉萍, 許華, 趙文, 蘇志堅, 李校堃, 張敏. 非促分裂型aFGF改構體的受體結合特性及其對NIH3T3細胞MAPK信號通路的影響,中國藥科大學(xué)學(xué)報,2005,36(2):179-182. 19.鄭青, 汪小鳳, 吳曉萍, 許華, 蘇志堅, 馮雅, 李校堃. 酸性成纖維細胞生長(cháng)因子對人臍靜脈血管內皮細胞一氧化氮生成的影響,暨南大學(xué)學(xué)報,2005, 26(4):455-459.
20.鄭青, 湛敏, 許華, 吳曉萍, 李校堃. nmhaFGF對SD大鼠缺血再灌注視網(wǎng)膜SOD、MDA、NO的影響,山東醫藥,2005,45(34):15-16.
近五年承擔的主要教學(xué)、科研項目
1. “治療老年性癡呆候選藥物--重組人酸性成纖維細胞生長(cháng)因子系列改構體的研究”,國家“重大新藥創(chuàng )制”科技重大專(zhuān)項(2009ZX09103-749)(主持);
2. “rhaFGF改構體的信號轉導研究”,國家863計劃項目子課題(主持);
3.“創(chuàng )傷愈合中與發(fā)育相關(guān)幾個(gè)重要問(wèn)題的應用基礎研究”,國家自然科學(xué)基金(30230370)(參加);
4.“重組人成纖維細胞生長(cháng)因子改構體新藥研究”,國家863計劃項目(2004AA2Z3C60)(參加); 5.“重組成纖維細胞生長(cháng)因子改構體系列新藥產(chǎn)業(yè)化研究”,廣東省科技計劃項目(2003C104005)(參加);
6.“創(chuàng )傷修復與組織再生類(lèi)基因工程產(chǎn)品的安全性評價(jià)”,廣州市科技計劃項目(2005J1-C0151)(參加);
7.“MaFGF基因工程一類(lèi)新藥項目”,橫向(參加)。